Piper Jaffray maintained a Neutral rating on TrovaGene (NASDAQ: TROV), and cut the price target to $4.00 (from $5.00), following ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS Change Analyst EPS View Analyst PT Change

Trovagene (TROV) Misses Q2 EPS by 3cAugust 4, 2016 5:42 PM Trovagene Reports Second Quarter 2016 Financial Results and AccomplishmentsAugust 4, 2016 4:15 PM Trading Radar for 8/4: Kellogg (K), MGM Resorts (MGM), Activision (ATVI), FireEye (FEYE), Weight Watchers (WTW) ReportAugust 3, 2016 2:51 PM